Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation.

Elevated very low-density lipoprotein (VLDL)-triglyceride (TG) secretion from the liver contributes to an atherogenic dyslipidemia that is associated with obesity， diabetes and the metabolic syndrome. Numerous models of obesity and diabetes are characterized by increased central nervous system (CNS) neuropeptide Y (NPY); in fact， a single intracerebroventricular (icv) administration of NPY in lean fasted rats elevates hepatic VLDL-TG secretion and does so， in large part， via signaling through the CNS NPY Y1 receptor. Thus， our overarching hypothesis is that elevated CNS NPY action contributes to dyslipidemia by activating central circuits that modulate liver lipid metabolism.

AGPAT， 1-acyl-glycerol-3-phosphate acyltransferase，ARF-1， ADP-ribosylation factor-1，ApoB， apolipoprotein B，CNS， central nervous system，Cyto， cytoplasmic，DAG， diacylglycerol，DGAT， diacylglycerol acyltransferase，ER， endoplasmic reticulum，FFA(s)， free fatty acid(s)，GAPDH， glyceraldehyde 3-phosphate dehydrogenase，HDAC-1， histone deacetylase-1，Lipin-1，NE， norepinephrine，NPY Y1 receptor，NPY， neuropeptide Y，Nuc， nuclear，PA， phosphatidic acid，PAP-1， phosphatidic acid phosphatase-1，PF， pair-fed，PL， phospholipid，PLD， phospholipase D，POMC， proopiomelanocortin，Phospholipid，RPL13A， ribosomal protein L13a，RT-PCR， real-time PCR，SCD-1， stearoyl-CoA desaturase-1，SNS， sympathetic nervous system，Sham， sham-denervation，Sx， sympathetic denervation，Sympathetic denervation，TG， triglyceride，Triglyceride，VLDL，VLDL， very low-density lipoprotein，Veh， vehicle，ZF， Zucker fatty，ad-lib， ad-libitum，icv， intracerebroventric